The IGF-1 family includes several research compounds. Each one acts within the insulin-like growth factor 1 (IGF-1) signaling system, or is derived from it. Growth hormone secretagogues work upstream at the pituitary to raise growth hormone, but these compounds interact more directly with IGF-1-related signaling.
This article covers four of them. IGF-1 LR3 and IGF-1 DES are two engineered analogs of IGF-1, while MGF and PEG-MGF relate to a naturally occurring IGF-1 splice variant. Every finding below is labeled as in vitro or animal. In vitro means the work was done outside a living body. These are research compounds, and nothing here is a statement about outcomes in people.
A note on molecular class: these four are not all the same kind of molecule. IGF-1 LR3 and IGF-1 DES are protein, or polypeptide, analogs of IGF-1. MGF is a shorter peptide derived from the E-domain of the IGF-1 splice variant. PEG-MGF is that peptide with polyethylene glycol attached. They are grouped here by the signaling axis they relate to, not by molecular class.
IGF-1 is a small polypeptide that signals through the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase. Activating that receptor drives two main routes inside the cell. One is the PI3K/Akt/mTOR pathway, associated with protein synthesis and cell survival, and the other is the Ras/MAPK pathway, associated with proliferation.
Most circulating IGF-1 is not free, however. It is largely bound to a family of six IGF-binding proteins (IGFBPs). These proteins hold on to IGF-1 and regulate how much is available to the receptor, and for how long. This binding-protein system matters particularly for understanding LR3 and DES, because both were designed, or selected, in ways that reduce IGFBP binding.
IGF-1 LR3, or Long R3 IGF-1, is a synthetic analog carrying two changes. An arginine replaces the glutamate at position 3, and a 13-amino-acid extension is added to the N-terminus, which is one end of the amino acid chain. Together these greatly reduce its affinity for the IGFBPs, while it continues to bind the IGF-1 receptor.
Working in cultured cells, Francis and colleagues reported in 1992 that LR3 was the most potent of a series of analogs.[1] They attributed that enhanced potency to reduced binding-protein interference, not to any increase in receptor affinity.[1]
In animals, Conlon and colleagues showed in 1995 that infusing LR3 IGF-I stimulated organ growth in guinea pigs under conditions where native IGF-1 did not.[2] They described LR3 IGF-I as an analog with much reduced affinity for IGF-binding proteins.[2] Both the cell and the animal findings are preclinical.
IGF-1 DES, more precisely des(1-3)IGF-1, reaches a similar outcome through a different structural change. Rather than adding residues, it removes the first three amino acids from the N-terminus of IGF-1, the tripeptide Gly-Pro-Glu.
That short N-terminal tripeptide is important for IGFBP binding, so removing it sharply reduces binding-protein interaction while the truncated molecule still engages the IGF-1 receptor. DES is not purely synthetic, and it occurs naturally in some tissues.
Ross and colleagues demonstrated in 1989 that IGF-binding proteins inhibited the biological activities of IGF-1 and IGF-2, but did not inhibit des(1-3)IGF-1.[3] That shows directly that the truncated form is much less affected by IGFBP-mediated inhibition.[3] This is why DES shows greater potency than intact IGF-1 in systems where IGFBPs are present. These are in vitro findings.
MGF is different from LR3 and DES, because it is not simply a modified form of mature IGF-1. It is a naturally occurring splice variant of the IGF-1 gene, designated IGF-1Ec in humans and IGF-1Eb in rodents, produced in muscle in response to mechanical strain and damage.
Its defining feature is a unique E-domain at the C-terminus, generated by alternative splicing. The synthetic peptide studied as MGF is typically that distinct E-peptide.
Researchers have reported that the E-domain peptide behaves differently from mature IGF-1. Yang and colleagues cloned the stretch-induced isoform in 1996.[4] Yang and Goldspink reported in 2002 that, in a myoblast cell model, the MGF E-domain increased proliferation while inhibiting terminal differentiation, the opposite behavior to mature IGF-1.[5] Myoblasts are immature muscle cells. In the same study, blocking the IGF-1 receptor with a specific antibody did not abolish the E-domain effect. That led the authors to conclude that a receptor other than IGF-1R mediates this action. The identity of that receptor remains unresolved. These are in vitro findings.
PEG-MGF is MGF, specifically the E-domain peptide, with polyethylene glycol chemically attached, a modification called PEGylation. PEGylation is a well-established general strategy for extending how long a peptide acts. It increases the peptide's effective size, so the peptide resists rapid enzymatic breakdown and clearance by the kidneys. That is relevant because native MGF has a very short half-life.
The evidence for PEG-MGF itself is much more limited, and there is very little primary, PubMed-indexed literature directly examining the PEGylated form. Its biological rationale is therefore largely extrapolated from research on MGF and the MGF E-peptide, together with the general use of PEGylation to extend peptide stability and exposure.
This article does not cite a PEG-MGF-specific primary source, because a verifiable one could not be established. Readers should treat claims about the PEGylated form as inferred from MGF research rather than directly demonstrated.
LR3 and DES share a clear mechanistic feature: both retain activity at IGF-1R while reducing interference from IGF-binding proteins. LR3 achieves this through an N-terminal extension and amino-acid substitution, while DES does so through N-terminal truncation.
MGF is less straightforward, because its E-peptide appears to act through a pathway separate from IGF-1R, promoting proliferation and delaying differentiation in the cell models studied.
PEG-MGF is the same E-domain peptide modified by PEGylation, with the aim of extending how long it persists rather than changing its underlying biological target.
The evidence behind these compounds is uneven. The analog work is grounded in cell and animal studies, much of it built around the biology of IGFBP evasion. For MGF, the strongest mechanistic findings come from a relatively small set of cell-model studies. The receptor responsible for the E-domain effect has still not been identified.
The PEG-MGF evidence gap noted above is substantial, and claims about the PEGylated form should be treated as extrapolations rather than direct experimental findings. None of these findings should be extrapolated to human outcomes.
IGF-1 LR3, IGF-1 DES, MGF and PEG-MGF all relate to the IGF-1 system, but they are not interchangeable. LR3 and DES are IGF-1 receptor agonists with reduced IGFBP binding, achieved through different structural modifications.
MGF is derived from an IGF-1 splice variant and has been reported to act through a distinct signaling route that is still unidentified. PEG-MGF is a PEGylated version of the MGF E-peptide, but the evidence specific to that modified form remains very limited.
The material discussed here is for research use only, and the evidence above describes what has been investigated, not what any individual should expect.
References
Growth hormone secretagogues (GHS) are molecules studied for their ability to make the pituitary gland release growth hormone (GH). Research so far has found that these molecules can reach the same end point by different routes or pathways. This article compar
NAD+, SS-31 and AICAR are all studied in relation to cellular energy metabolism and mitochondrial function, but they work in different ways. NAD+ is an essential coenzyme that several classes of enzyme depend on. SS-31 is a mitochondria-targeted peptide that a
GHK-Cu, Matrixyl, PAL-GHK and Snap-8 all appear in dermal research, but they do not all act through the same biological pathway. This article discusses GHK-Cu, Matrixyl and PAL-GHK in relation to collagen and extracellular matrix (ECM) biology. Snap-8 is studi
The myostatin pathway is one of the clearest biological systems involved in limiting skeletal muscle growth. GDF-8, Follistatin and ACE-031 each act at a different point in this pathway: GDF-8 provides the inhibitory signal, and Follistatin binds and neutraliz
Vesilute is a trade name for the dipeptide Glu-Asp. The one indexed animal study found no difference from its amino acids on the three endpoints it measured.
Thymulin is a zinc-dependent thymic nonapeptide. Its human trials date from the 1980s, it is approved nowhere, and its newest evidence is preclinical.
